Lixa Pty Ltd
- Biotech – industrial & Environmental
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Biotech – food & agriculture
Australian biotech developing first in class, first in therapeutic area drugs to reverse antimicrobial resistance across broad classes of antibiotics, biocides and antiseptics in planktonic & biofilm bacterial infections or contaminations. Lixa's drugs act via a novel metabolic switch mechanism of action that is conserved across bacterial species and independent of bactericidal or bacteriostatic mechanisms. Clinical stage lead compounds for inhaled and for iv/oral routes are developed as concomitant therapies to antimicrobial treatments. The technology is easy to integrate into existing standard of care and has strong anti-inflammatory efficacy.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}